Compare Enveric Biosciences Inc (ENVB) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Keysight Technologies Inc — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Keysight Technologies Inc trades at $322.57 (market cap $55.15B). The key difference: Keysight Technologies Inc is far larger — about 10366.5× Enveric Biosciences Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | KEYS | |
|---|---|---|
Market Cap | $5.32M | $55.15B |
Sector | Health | Technology |
52-Week High | $17.40 | $373.34 |
52-Week Low | $1.28 | $158.51 |
Enterprise Value | $408.82K | $55.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Keysight Technologies (KEYS) trades at $314.15, down 3.56% today, with a neutral technical outlook despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.87 exceeding expectations by 24%. Recent developments include partnerships with the European Space Agency and new product launches in cybersecurity testing and photonics design automation, positioning the company for growth in 5G and AI-driven markets.
Wall Street maintains strong bullish sentiment with 81% buy ratings and a $396.56 consensus price target, representing 26% upside potential. However, elevated valuation ratios (P/E 51.97, P/S 9.14) and recent cash flow volatility present risks. The company's expansion into high-growth technology sectors provides opportunity, but investors should monitor execution on projected 2026 revenue growth to $6.1B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
